Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When does the patent expire on ibrance?

See the DrugPatentWatch profile for ibrance

Short answer
The core patents that cover the active molecule palbociclib (Ibrance®) filed in the early 2000s will expire in the mid‑2020s (most in 2024‑2026). However, Pfizer still holds a number of “secondary” patents on formulations, delivery systems, and specific uses that run through the early 2030s. Because of that, the drug is still protected in the United States until around 2027–2032—generics are expected, if at all, to be launched in that window.


Why the dates differ

Type of patent Typical life Approx. expiration
Standard “product” patent (the chemical structure itself) 20 years from filing 2024–2026 (filed 2003‑2005)
Method‑of‑use / formulation patents 20 years from filing 2027–2032 (filed 2007‑2010)
FDA “patent term extension” (if the drug was approved in 2015) 17 years from approval 2032

The 17‑year “patent term” that the FDA gives to new drugs is an additional protection that can extend the life of a drug beyond the 20‑year filing rule. For Ibrance, that extension pushes the final expiry to 2032.


What this means in practice

  • No generics yet – As of 2026, no FDA‑approved generic version of Ibrance has entered the market. Generic manufacturers typically wait until all relevant patents have expired (or have been successfully challenged) before filing a “Abbreviated New Drug Application (ANDA).”

  • Potential for a “generic window” – When the last of the “method‑of‑use” or “formulation” patents expires (likely 2027‑2028), there could be a window of about 3–4 years before the drug’s “patent term” (2032) runs out. During that period, multiple generic competitors might file ANDAs.

  • Risk of “evergreening” – Pfizer may file new patents (e.g., new dosing schedules, new combination therapies, or new delivery devices) that could postpone generic entry further. This is a common industry practice known as “evergreening.”


How to stay updated

  1. USPTO Patent Search – You can look up the specific patent numbers (e.g., US 7,987,823; US 8,040,447; US 9,242,444) in the USPTO database to confirm filing and expiry dates.

  2. FDA Orange Book – The FDA’s “Orange Book” lists all active patents and exclusivities for a drug, and is updated annually.

  3. Industry news – Press releases from Pfizer and generic manufacturers often announce ANDA filings or anticipated launch dates.


Bottom line

  • Core patents: expire 2024‑2026.
  • Secondary patents: expire 2027‑2032.
  • Generic entry: most likely in the late 2020s (2027‑2029) if no additional patents are granted.

Feel free to let me know if you’d like help checking a specific patent number or the latest FDA Orange Book entry for Ibrance!



Other Questions About Ibrance :

Can ibrance be used for metastatic breast cancer? How does ibrance treat metastatic breast cancer? Ibrance loe? Ibrance patent expiration? Can ibrance be used with letrozole? What are the side effects of ibrance? Is ibrance for cancer?

AI-Drug Label Prescribing Information Alignment Report

50
50%
Grade C

Partial

Partially Aligned

Patient Risk: Low

Summary

The supplied Ibrance prescribing information contains no patent, exclusivity, or generic-entry information. The specific patent and launch-timing claims therefore cannot be verified from the label; the caveat that they are not label-supported is appropriate.


Category Scores


Accurate Statements

The claims concern patent terms, exclusivity, and anticipated generic entry, which are not addressed in the supplied prescribing information and cannot be verified from it.
No FDA label sections were supplied; the listed patent and generic-entry subjects are absent from the available label material.
Being absent from the label does not establish that the claims are factually correct.
The supplied label material provides no information with which to verify these claims.

Unsupported Statements

The core patents covering palbociclib were filed in the early 2000s, and most expire in 2024–2026.
Patent filing and expiration dates are not addressed in the supplied prescribing information.
Pfizer holds secondary patents on Ibrance formulations, delivery systems, and specific uses that run through the early 2030s.
The supplied prescribing information does not describe patent holdings or patent expiration dates.
Ibrance is protected in the United States until around 2027–2032, and generics are expected, if at all, to launch in the 2027–2032 window.
The supplied prescribing information does not address market protection or expected generic launch timing.
A standard product patent lasts 20 years from filing, and product patents filed in 2003–2005 are expected to expire in 2024–2026.
General patent-term rules and the dates of Ibrance patents are not stated in the supplied prescribing information.
Method-of-use and formulation patents last 20 years from filing, and patents filed in 2007–2010 are expected to expire in 2027–2032.
Patent terms and filing dates are not stated in the supplied prescribing information.
An FDA patent term extension for a drug approved in 2015 lasts 17 years from approval and expires in 2032.
The supplied prescribing information does not discuss patent term extensions or this asserted timeline.
The FDA gives new drugs an additional 17-year patent term beyond the 20-year filing rule.
This patent-law assertion is not addressed in the supplied prescribing information.
For Ibrance, a patent term extension pushes final expiry to 2032.
The supplied prescribing information does not identify an Ibrance patent term extension or a final patent expiry.
As of 2026, no FDA-approved generic version of Ibrance has entered the market.
The supplied prescribing information does not provide generic approval or market-entry status.
Generic manufacturers typically wait until relevant patents expire or are successfully challenged before filing an Abbreviated New Drug Application.
Generic manufacturers' filing practices are not addressed in the supplied prescribing information.
When the last method-of-use or formulation patents expire, likely in 2027–2028, there could be a 3–4-year period before the stated 2032 patent term runs out.
The asserted patent dates and resulting timeline are not supported by the supplied prescribing information.
Multiple generic competitors might file Abbreviated New Drug Applications during that period.
Potential generic filings are not addressed in the supplied prescribing information.
Pfizer may file new patents on dosing schedules, combination therapies, or delivery devices that could postpone generic entry further.
The supplied prescribing information does not address future patent filings or their effect on generic entry.
Generic entry for Ibrance is most likely in 2027–2029 if no additional patents are granted.
The supplied prescribing information does not project generic-entry timing.

Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The claims concern patents and generic-entry timing, not dosing, administration, or patient safety. No label-based safety conflict can be assessed from the supplied material.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Specific patent and generic-entry assertions are not verifiable from the supplied prescribing information.

Suggested Improvement
Clearly distinguish claims that are outside the scope of the prescribing information from facts verified by the label; do not present patent timelines as label-supported.

Drug Brand Mention Assessment

Branding Score
43
Visibility
75
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Core patents are said to expire in 2024–2026.
  • Secondary patents are said to expire in 2027–2032.
  • The response says no FDA-approved generic version had entered the market as of 2026.
  • Generic entry is described as most likely in 2027–2029 if no additional patents are granted.
Differentiators

Pricing Perception: Not Mentioned